Assessment of serum interleukin 5 levels in patients with psoriasis vulgaris.

Background: Psoriasis is an autoimmune disease that is chronic, inflammatory, and caused by T cells. It affects the skin, nails, mucous membranes, and joints, yet not the hair. It affects about 2–3% of people worldwide, equally divided between the sexes. It affects people from 1 to 18 years old. Objective: The objective was to assess the serum level of IL-5 and establish a relationship between it and the severity of psoriasis vulgaris in patients with mild, moderate, and severe cases. Materials and Methods: This case–control study was conducted over the course of six months, from November 2020 to April 2021 at the Beni-Suef University Hospital’s outpatient clinic for dermatology, venereology, and andrology. Fifty patients with varying degrees of psoriasis vulgaris and forty age- and sex-matched, seemingly healthy controls were included in the study. A physical examination, history, and family history were all taken into consideration for the diagnosis, which was also supported by a thorough cutaneous examination of every case. The Psoriasis Area Severity Index (PASI) score was used to grade them. Furthermore, 5 mL of blood was taken out for testing. Studies pertaining to IL-5. Results: IL-5 levels were noticeably higher in the PV group than in the control group. Conclusion: The current study may add to our understanding and provide some insight into the potential involvement of IL-5 in the pathophysiology of psoriasis. Biologic treatments against IL-5 may be useful in the treatment of psoriasis. [ABSTRACT FROM AUTHOR]